Ceragenix Pharmaceuticals

Innovations & ideas, 7/2
Denver Post - A Denver-based biotechnology company is looking at ways to treat eczema in children without using steroids. Ceragenix Pharmaceuticals Inc. said last week that it will begin a study of its topical cream Epiceram to see if it works just as well on

Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006
Genetic Engineering News - Ceragenix Ticker Symbol & Exchange: CGXP Investor Relations Contact: Robert Stanislaro Investor Relations Contact Phone: 212-850-5657 Web: www.ceragenix.com Date of Presentation: May 15 at 5:15

Latest News
dBusinessNews.com - Files Countersuit against Smart-tek DENVER -- America's best respected radio frequency identification (RFID) consulting Denver: FDA Grants Ceragenix's Request for Cerashield(TM) to be Reviewed as a Device; Ceragenix to Seek Expedited Review

Latest News
dBusinessNews.com - Ceragenix Obtains IRB Approval for Eczema Clinical Study; Study to Compare EpiCeram(R) to Mid-Strength Topical Steroid in Treatment of Children with Moderate-to-Severe Eczema DENVER -- Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company

Colorado business, 5/2
Denver Post - Ceragenix Pharmaceuticals Inc. , a Denver-based biopharmaceutical company, announced Monday that Steven Porter, its chairman and chief executive, will make a presentation at the Rodman & Renshaw third annual Global Healthcare Conference on May 15 in